Neuro Startup Makes Debut With $20.9M From Novo, Johnson & Johnson Post author:Sam Post published:February 8, 2018 Post category:BioPharma Syndesi will work to modulate the synaptic vesicle protein SV2A. Source: BioSpace You Might Also Like Ignyta To Present At 2016 Healthcare Conference July 8, 2016 INVO Bioscience Reports First Quarter 2017 Financial Results May 15, 2017 biOasis Announces Voting Results For 2017 Annual Meeting September 21, 2017
